Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusion Antibodies Plc ( (GB:FAB) ) just unveiled an announcement.
Fusion Antibodies plc, a specialist in therapeutic and diagnostic antibody discovery and engineering, has reported an internal share transfer involving its non-executive chair. The company operates integrated antibody development platforms such as OptiMAL and OptiPhage and targets the fast-growing global antibody therapeutics market, which is forecast to approach $500 billion by 2029.
The company disclosed that Non-Executive Chair Simon Douglas has transferred 200,000 ordinary shares to his daughters at no consideration. Following the transaction, he directly holds 861,062 shares, or about 0.69% of the issued share capital, a change that fine-tunes his personal holdings but does not alter overall ownership structure or day-to-day operations.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £15.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance and concerning valuation. While there is some technical momentum, the negative P/E ratio and lack of profitability are significant risks. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Northern Ireland-based contract research organisation specialising in pre-clinical antibody discovery, engineering and expression services for human and veterinary therapeutics and diagnostics. The company provides integrated end-to-end offerings including antigen design, antibody generation, optimisation, humanisation via its CDRx platform, and cell line development for a global pharma and biotech client base that includes major pharmaceutical companies.
Average Trading Volume: 854,913
Technical Sentiment Signal: Buy
Current Market Cap: £18.44M
See more insights into FAB stock on TipRanks’ Stock Analysis page.